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Key Points
Whole-exome sequencing of CLL patients who relapsed after FCR treatment revealed frequent
mutations in RPS15.
RPS15 mutations are likely to be early clonal events and confer poor prognosis.

Abstract
Fludarabine, cyclophosphamide, and rituximab (FCR) is first-line treatment of medically fit chronic
lymphocytic leukemia (CLL) patients; however, despite good response rates, many patients eventually
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relapse. Although recent high-throughput studies have identified novel recurrent genetic lesions in adverse
prognostic CLL, the mechanisms leading to relapse after FCR therapy are not completely understood. To
gain insight into this issue, we performed whole-exome sequencing of sequential samples from 41 CLL
patients who were uniformly treated with FCR but relapsed after a median of 2 years. In addition to
mutations with known adverse-prognostic impact (TP53, NOTCH1, ATM, SF3B1, NFKBIE, and BIRC3), a
large proportion of cases (19.5%) harbored mutations in RPS15, a gene encoding a component of the 40S
ribosomal subunit. Extended screening, totaling 1119 patients, supported a role for RPS15 mutations in
aggressive CLL, with one-third of RPS15-mutant cases also carrying TP53 aberrations. In most cases,
selection of dominant, relapse-specific subclones was observed over time. However, RPS15 mutations
were clonal before treatment and remained stable at relapse. Notably, all RPS15 mutations represented
somatic missense variants and resided within a 7 amino-acid, evolutionarily conserved region. We
confirmed the recently postulated direct interaction between RPS15 and MDM2/MDMX and transient
expression of mutant RPS15 revealed defective regulation of endogenous p53 compared with wild-type
RPS15. In summary, we provide novel insights into the heterogeneous genetic landscape of CLL relapsing
after FCR treatment and highlight a novel mechanism underlying clinical aggressiveness involving a
mutated ribosomal protein, potentially representing an early genetic lesion in CLL pathobiology.

Introduction
The clinical course of patients with chronic lymphocytic leukemia (CLL) is highly variable and ranges
from rapid disease progression requiring early treatment to survival for decades without any need for
therapy. Today, the gold standard first-line regimen in young, medically fit CLL patients is
chemoimmunotherapy (ie, the combination of fludarabine, cyclophosphamide, and an anti-CD20-antibody,
rituximab [FCR]).1,2 Although this therapy is initially effective, achieving a 90% overall response rate,
most patients will relapse, often with a more aggressive disease and in rapid need of secondary treatment,
especially if relapse occurs within a short time (<2-3 years) after receiving FCR.1,2
With the advent of next-generation sequencing, new insights into the molecular landscape of CLL have
been achieved.3-8 In addition to the well-documented TP53 aberrations, recurrent somatic mutations were
recently discovered within genes involved in key cellular processes (eg, NOTCH signaling, RNA splicing,
nuclear factor κB signaling). Such mutations tend to be enriched in high-risk CLL patients and have been
associated with inferior outcome and even chemo-refractory disease.4-13 New technologies have also
facilitated the exploration into the clonal architecture of CLL, not only at a single time point, but also
throughout the disease course, by analyzing longitudinal samples.14,15 From these pioneering studies, it
became evident that subclonal mutations (ie, variants detected in only a fraction of the tumor population)
could be present at low frequencies, even remaining undetected, at early stages of the disease; however,
they can be positively selected as the disease progresses, particularly after several lines of therapy.14,15
The detrimental effect of low-frequency variants in CLL was recently illustrated whereby microclones
carrying TP53 mutations could be detected at diagnosis using ultra-deep sequencing; these microclones
appeared to expand over time and were found to have a clinical impact similar to clonal TP53
mutations.16,17 At present, definitive conclusions cannot be drawn regarding the dynamics of clonal
evolution in relation to specific treatment regimens because relevant studies have investigated relatively
small cohorts of, more importantly, heterogeneously treated patients.
To overcome these limitations, we applied whole-exome sequencing (WES) of longitudinal samples
collected from 41 patients with CLL who were homogeneously treated with FCR and exhibited a good
initial response but relapsed within a median of 2 years. In addition to gene mutations previously
associated with poor outcome, we identified recurrent mutations in RPS15, a gene encoding a ribosomal
protein, in almost 20% of FCR-relapsing patients. Screening in extended cohorts confirmed an increased
frequency of RPS15 mutations in adverse prognostic CLL. In addition to the established role of RPS15 in
protein translation, we verified the recently reported interaction between RPS15 and MDM2/MDMX18
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and showed reduced stabilization and increased p53 degradation in RPS15 mutants compared with wildtype (wt) RPS15, indicating a novel molecular mechanism involved in the pathobiology of CLL.

Methods
Patient material
Forty-one CLL patients from 7 collaborating institutions in Sweden, Greece, Italy, France, the Czech
Republic, the United Kingdom, and Germany were included for mutational screening using WES. All
cases were diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia
guidelines and displayed a typical CLL phenotype.19 All patients had received FCR treatment and had
either obtained a complete remission (CR; n = 32) or partial remission (n = 9); at least 4 rounds of
treatment were required for patients exhibiting partial remission, whereas patients with CR were included
in the study irrespective of the number of treatment cycles. Response and relapse criteria were adopted
according to the International Workshop on Chronic Lymphocytic Leukemia guidelines.19 Patients
relapsed at a median of 2.17 years (range, 1-11 years) after the first round of treatment; the main
characteristics of the analyzed cases are summarized in supplemental Table 1, available on the Blood Web
site. Peripheral blood samples were collected before the start of FCR treatment (median, 0.1 years; range,
0-2.85 years) and after treatment relapse (median, 0.51 years; range, 0-3.46 years). Constitutional DNA
from sorted T cells or buccal swabs was available for 28 patients. Our extended cohort for targeted
resequencing of exon 4 in RPS15 comprised an additional 790 CLL samples (605 adverse prognostic and
185 favorable prognostic patients) from the previously mentioned institutions and from additional
institutions in Greece, The Netherlands, and the United States as well as 30 cases with Richter
transformation. In a second validation cohort, samples from 329 untreated patients enrolled in the UK
Leukaemia Research Fund Chronic Lymphocytic Leukaemia Trial 4 (CLL4) clinical trial were
investigated.20 The main clinicobiological characteristics of the analyzed cases are summarized in
supplemental Tables 2 and 3. Informed consent was collected according to the Helsinki Declaration and
approval was granted by local ethical review committees.
WES and data analysis
Before WES, all CLL samples were fluorescence-activated cell–sorted or underwent negative selection to
enrich the tumor cell population (>95%), with the exception of 6 samples for which viable frozen cells
were not available (tumor percent within these 6 samples was >60%). High-quality genomic DNA was
obtained using Qiagen extraction kits. Libraries for WES were constructed using the TruSeq Exome
Enrichment Kit (Illumina) and sequenced on an Illumina HiSeq 2000. The raw sequencing reads were
processed using the bcbio-nextgen framework. Reads were aligned to the Hg19 reference genome using
BWA-mem, version 0.7.10,21 realigned using GATK, version 3.2,22 and polymerase chain reaction
duplicates were marked using Sambamba, version 0.4.7. Single nucleotide variants (SNV) and indels were
detected using VarScan2, version 2.3.6.23 Samples with matched germline DNA were analyzed using the
somatic mode and the remaining samples using the mpileup2cns mode, both with a 10% variant allele
frequency cutoff. Samples with matched constitutional DNA were analyzed in all targeted regions as
specified by the manufacturer. From this screening, genes mutated in ≥2 samples at relapse were screened
in samples without matched normal DNA. Somatic copy-number aberrations were derived from WES data
using EXCAVATOR24 and the output was segmented using the DNAcopy R package. A high concordance
was observed between WES somatic copy-number aberrations and aberrations detected by fluorescence in
situ hybridization (supplemental Table 4).
Sanger sequencing
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Bidirectional Sanger sequencing of selected variants and the hotspot region of RPS15 (exon 4) was
performed using the BigDye Terminator, v3.1, Cycle Sequencing Kit and an ABI 3730 DNA Analyzer
(Life Technologies). Primers are available upon request.
Analysis of clonal composition
SciClone25 enabled clustering analysis of variant allele frequencies of both the pretreatment and relapse
mutations. All somatic variants, including synonymous variants and variants in noncoding regions, with
coverage ≥20× were included in the analysis. The algorithm excludes regions affected by copy-number
gain or losses; these data were obtained from EXCAVATOR.24 This analysis focuses on detecting mutation
clusters and delineating their intrinsic relationship rather than assigning the exact cell fraction affected by
the mutation. For analysis of mutations specific to the pretreatment or relapse sample, the position was
examined in the reference-called sample to ensure sufficient read depth. Assuming that the variant allele
frequency of the largest detectable cluster corresponds to the total tumor population, the tumor fraction of
each cluster was calculated in relation to the largest cluster at each time point.
Cell culture
Because of the inherent difficulties in transfecting existing CLL cell lines, a well-characterized TP53wt
colorectal cancer cell line HCT116 (ATCC) was selected; the cell line was maintained in McCoy’s 5A
medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (all from Thermo
Fisher Scientific Inc) and cultured in a humidified atmosphere of 5% CO2 and 37°C.
Transient transfections
Myc-DDK tagged RPS15 (RC210640), turbo green fluorescent protein (tGFP) tagged MDM2
(RG219518), and tGFP tagged MDMX constructs (RG209620) were purchased from Origene. To generate
RPS15 expression vectors with p.P131S or p.G132A mutations, site-directed mutagenesis was performed
using the QuikChange II kit (Agilent Technologies) with the following primers:
GGCCCCGATGGGGACCGGCC (P131S fwd), GGCCGGTCCCCCATCGGGGCC (P131S rev),
GGCCCCGATGGCGGGCCGGCC (G132A fwd), and GGCCGGCCCGCCATCGGGGCC (G132A rev).
The presence of mutations was confirmed by direct Sanger sequencing. Transfection of HCT116 colorectal
cancer cells was performed using lipofectamine 2000 (Thermo Fisher Scientific Inc) according to the
manufacturer’s instructions.
Western blot
Cells were lysed in NP40 buffer supplemented with phosphatase/protease inhibitors (Roche); protein levels
were quantified by colorimetric assay (Thermo Fisher Scientific Inc). An equal amount of total protein was
run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel (NuPAGE Novex 4% to 12% BisTris Gels; Thermo Fisher Scientific Inc) and transferred to nitrocellulose membranes using iBlot (Thermo
Fisher Scientific Inc). Following incubation with primary antibodies, the membranes were washed in
phosphate-buffered saline and incubated with secondary horseradish peroxidase–coupled goat anti-mouse
and horse anti-rabbit antibodies (#7074 Sigma, 1:10 000; #7076 Sigma, 1:5000). Immunoreactive proteins
were visualized using ECL western blotting detection reagent (GE Healthcare) on the ImageQuant LAS
4000 imaging system (GE Healthcare).
Coimmunoprecipitation
HCT116 cells were cotransfected, as described previously, using an equal amount of plasmids. For
immunoprecipitation, cells were harvested 24 hours’ posttransfection and 500 μg of the total cell lysates
were precleared using Protein A/G Plus Agarose beads (20423, Thermo Scientific) followed by incubation
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4768426/?report=printable
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with 2 μg of either anti-DDK (TA50011-100, Origene) or anti-tGFP (TA150041, Origene) antibody
overnight at +4°C. Proteins were captured on preblocked Protein A/G Plus agarose over 3 hours and
immunocomplexes were washed with 1× phosphate-buffered saline and 0.1% NP40. Bound proteins were
detected by western blot using anti-DDK (dilution 1:1000) and anti-tGFP (dilution 1:1000) antibodies.
Cycloheximide-chase assay
The stability of p53 in the presence of RPS15 was detected by blocking protein synthesis using
cycloheximide. Briefly, 24 hours after transfection, HCT116 cells were treated with 100 μg/mL
cycloheximide and harvested at indicated time points. Cell lysates (40 μg) were analyzed by western blot
(detailed previously) using anti-p53 (DO-1, Santa Cruz Biotechnology), anti-b-actin (#A5316 Cell
Signaling, dilution 1:2000), and anti-c-DDK (TA100023 Origene, dilution 1:2000) antibodies. Protein
bands were quantified using Image J software (http://imagej.nih.gov.medproxy.hofstra.edu/ij).
Ubiquitination assay
For p53 ubiquitination assay, 24 hours after transfection with indicated plasmids, cells were treated with 30
μM MG132 (Selleckchem, S2619) for 4 hours and lysed in NP40 lysis buffer supplemented with 10 mM
N-Ethylmaleimide (Sigma-Aldrich). Cell lysates were processed as described previously and an equal
amount of total protein was resolved on 4% to 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. Immunoblotting was performed with anti-p53 (DO-1, Santa Cruz Biotechnology) and antiDDK antibodies.
Statistical analysis
Differences in frequencies were evaluated using descriptive statistics. Associations between categorical
variables were assessed using the χ2 test for independence. Overall survival (OS) was calculated from the
date of sampling until the date of last follow-up or death. Survival curves were constructed using the
Kaplan-Meier method, and the log-rank test was used to determine differences between survival
proportions. For all comparisons, P values were 2-sided and a significance level of P < .05 was set. All
statistical analyses were performed using Statistica Software 10.0 (Stat Soft Inc).

Results
Mutational landscape in FCR-relapsing CLL
WES of 110 samples collected from 41 CLL patients who relapsed after receiving FCR treatment reached
a mean effective coverage of ∼60× (supplemental Table 5). For the 28 patients with matched germline
DNA, 1191 somatic variants were detected in the pretreatment samples and 1334 in the relapse samples. A
total of 430 variants in the pretreatment samples and 499 in the relapse samples concerned
nonsynonymous mutations, rendering an average of 15.2 (range, 3-24) and 17.6 (range, 2-32) nonsilent
mutations per case, respectively (Figure 1A). When comparing the 6 classes of transition and transversion
mutations in the pretreatment sample vs the relapse-specific mutations, we observed a significant increase
in C•G→A•T transversions at relapse (P = .005, Figure 1B).
Mutational screening revealed high frequencies of mutations linked to poor outcome in both pretreated and
relapse samples, including NOTCH1, TP53, ATM, SF3B1, MGA, and BIRC3; similar frequencies were
detected in genes recently found to be enriched in patients with aggressive disease (ie, NFKBIE and
EGR2)6-13,26-28 (supplemental Table 6; a complete list of mutated genes is provided in supplemental
Tables 7 and 8). Twenty-six (63.4%) of 41 patients carried mutations in at least 1 of the previously
mentioned genes at pretreatment rising to 33/41 (80.5%) at relapse (Figure 1C), whereas 12 (29.2%) and
15 cases (36.6%) harbored 2 or more coexisting mutations before the start of treatment and at relapse,
respectively.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4768426/?report=printable
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Intriguingly, a high frequency of mutations was detected in RPS15 (pretreatment 7/41 cases, 17.1%; at
relapse 8/41 cases, 19.5%), which encodes the ribosomal protein S15, a component of the 40S ribosomal
subunit; thus far, very few CLL cases carrying mutations within this gene have been reported.9,28 All
mutations found within RPS15 were missense SNVs (n = 7) or multiple nucleotide variants (n = 1) and,
with the exception of 1 SNV, clustered to a 7 amino-acid evolutionarily conserved region within exon 4 (
Figure 2A; supplemental Figure 1). Of note, 3 RPS15-wt cases carried mutations within 2 other ribosomal
genes (ie, RPSA and RPS20) (supplemental Table 7). All RPS15 mutations were confirmed by Sanger
sequencing and their somatic origin was verified in all cases with available matched germline DNA
(supplemental Table 9). All 8 RPS15-mutant patients carried unmutated immunoglobulin heavy variable
(IGHV) genes (U-CLL); 3 had TP53 aberrations and another 3 had 11q deletion (Figure 1C). None of the
RPS15 mutated cases showed any indication of copy number aberrations involving the RPS15 gene
(19p13.3), based on copy number WES data.24 Six of the 8 RPS15-mutant cases achieved CR and 5/8
relapsed within 3 years (Figure 1C). However, no difference in time to relapse (median 22 months vs 26
months, P = .78) or OS (median 114 months vs not reached, P = .89) was seen between RPS15-mutated vs
wt patients.
RPS15 mutations are enriched within aggressive CLL
Prompted by our finding of RPS15 mutations, we next performed targeted resequencing of the RPS15
hotspot (exon 4) in an extended CLL series (n = 790), intentionally enriched for cases displaying adverse
prognostic profiles (n = 605; supplemental Table 2), and found an additional 36 mutations in RPS15
(36/605, 6%, Figure 2B-C). In contrast, none of the 185 more favorable prognostic, IGHV-mutated CLL
patients carried RPS15 mutations (supplemental Table 2). Enrichment of TP53 aberrations (ie, TP53
mutations and/or del(17p)) was identified in RPS15-mutant versus wt RPS15 cases (36% vs 18%, P < .01)
and a paucity of trisomy 12 (3% vs 13%, P < .05) and SF3B1 mutations (6% vs 20%, P < .05), similar to
the discovery cohort.
Survival analysis (n = 613) showed an equally poor OS of RPS15-mutant cases with coexisting TP53
aberrations (noteworthy is that these cases generally carried biallelic TP53 mutation/deletion) as cases
harboring TP53 aberrations only (Figure 2E); a nonsignificant trend (P = .15) of worse OS for
RPS15mut/TP53abn cases was observed. RPS15-mutant patients without concomitant TP53 aberrations had
an OS similar to other aggressive CLL subgroups (patients with del(11q), NOTCH1, or SF3B1 mutations
vs RPS15-mutated; P = .30, Figure 2E-F), whereas the 10-year survival was lower for this subgroup
compared with the remaining RPS15wt/TP53wt patients (0% vs 59%, P = .031; supplemental Figure 2A),
pointing to a dismal prognosis for RPS15-mutated CLL. Similar results were obtained in the UK CLL4
trial cohort,29 which included CLL cases requiring treatment and randomized to 1 of chlorambucil,
fludarabine, or fludarabine and cyclophosphamide. Overall, 12/329 (3.6%) cases within this cohort carried
RPS15 mutations (Figure 2D), and RPS15mut/TP53wt patients displayed an OS similar to other adverse
prognostic groups (supplemental Figure 2B, supplemental Table 3B). Finally, we analyzed 30 cases with
Richter syndrome (RS; ie, CLL transformed into diffuse large B-cell lymphoma) and only a single case
was found to carry an RPS15 mutation (Figure 2B); this mutation was also observed in the preceding CLL
phase.
RPS15 mutations as potential early initiating events
Temporal dynamics of subclonal composition were investigated for 25/28 samples with matched germline
DNA using SciClone.25 This analysis revealed clusters of mutations that potentially correspond to
individual (sub)clones. Overall, 2 general patterns were observed; the vast majority of cases exhibited
either relapse-specific mutations/clusters that had expanded to become dominant or clusters that expanded
more than 20% in (median) allele frequency (n = 23), whereas the remaining 2 cases demonstrated a more
stable intraclonal composition over time (supplemental Figures 3 and 4, supplemental Table 11).
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4768426/?report=printable
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Pretreatment and relapse-specific mutations were observed in all cases, indicating a branched, rather than
linear, evolution pattern:30 2 characteristic examples are shown in Figure 3. Although the majority of
EGR2 and BIRC3 mutations expanded upon relapse, NOTCH1 and TP53 mutations remained stable or
expanded and mixed patterns were observed for ATM and SF3B1 mutations (Figure 3C-E; supplemental
Figure 5). Notably, in all but 1 case with RPS15 mutations, the variants were detected at high allelic
frequencies at both time points (median pretreatment 47.7%, median at relapse 40.2%, range 29% to 56%),
implying that RPS15 mutations may represent early initiating events in pathogenesis of CLL. RNA
sequencing data were available for 4 RPS15-mutated cases and revealed similar variant allele frequency as
WES data (supplemental Table 12). Of the available cases from both the screening and validation cohorts
with variant allele frequency data for both RPS15 and TP53 (n = 7), 3 showed clonal RPS15 and subclonal
TP53 mutations (<25%), whereas the remaining cases showed both clonal RPS15 and TP53 mutations
(supplemental Table 13). The timing of the analysis in relation to diagnosis, treatment initiation, and
relapse for RPS15 mutant cases is depicted graphically in supplemental Figure 6.
Mutated RPS15 leads to impaired p53 stability
In addition to its role in protein translation, free RPS15 protein has been shown to stabilize p53 by
interfering with the MDM2-p53-MDMX network by directly binding to MDM2 and inhibiting p53
degradation.18 We thus sought to investigate the potential effect of RPS15 mutations on p53 regulation.
Because most (if not all) established CLL cell lines are Epstein-Barr virus—transformed, and 1 of the most
used cell lines (MEC-1) carries a TP53 defect, we chose to use a well-characterized TP53wt cell line
(HCT116) for the transient expression of 2 recurrent RPS15 mutations (p.P131S and p.G132A; Figure 2A)
and wt RPS15. First, we performed coimmunoprecipitation and confirmed the physical interaction both
between RPS15 and MDM2 and RPS15 and MDMX (Figure 4A-B). A higher binding efficiency to
MDM2 was noted for RPS15P131S compared with RPS15G132A and wt. Second, we studied the impact of
these 2 mutants on p53 stabilization and found that the RPS15G132A mutant consistently displayed an
impaired ability to regulate endogenous p53, showing a distinct reduction in p53 stabilization over time
compared with wt RPS15. The analysis for the RPS15P131S mutant disclosed a minor reduction (3
independent experiments are shown in Figure 4C-D and supplemental Figure 7). Finally, to test whether
reduced p53 is a consequence of ubiquitin-mediated degradation, we performed p53 ubiquitination
experiments that revealed a higher level of ubiquitination in both mutants compared with wt RPS15 (
Figure 4E).

Discussion
Previous large-scale screening efforts in CLL have mainly focused on treatment-naïve patients or included
samples at various time points from mixed patient groups receiving different treatment regimens.4-7,14 By
applying WES to samples collected longitudinally from CLL patients relapsing after FCR therapy, we
aimed to describe the genomic landscape and the temporal dynamics of genetic lesions in a
homogeneously treated patient group. Our prime finding concerns mutations within RPS15, a gene
encoding a component of the ribosomal S40 subunit, which were present in almost 20% of relapsing CLL
patients. In extended analyses, we noted that RPS15 mutations were primarily found in aggressive CLL
and were clonal in the pretreatment sample in the majority of cases. Finally, our pilot functional analysis
indicates that RPS15 mutations may lead to defective p53 stability and increased degradation compared
with wt RPS15, representing a potential novel mechanism in CLL pathobiology.
In line with previous sequencing studies of CLL patients treated with chemoimmunotherapy, we observed
that the average frequency of somatic mutations remained largely unchanged at relapse (15.2 and 17.6
mutations per case before therapy and at relapse, respectively), indicating that FCR treatment per se is not
intrinsically mutagenic.6,14 Nevertheless, a significant increase in C•G→A•T transversions at relapse was
noted when comparing pretreatment and relapse-specific mutations. This is in line with previous
31
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observations in relapsing acute myeloid leukemia31; however, the mechanism responsible for this
enrichment of transversions at relapse remains elusive.
In a substantial proportion of cases, mutations within genes recently suggested to impact outcome or even
treatment response were identified (eg, NOTCH1, TP53, ATM, SF3B1, MGA, BIRC3, EGR2, NFKBIE),613,26,27
and the frequency of mutations within at least 1 of these genes increased from 63.5% before
treatment to 80.5% at relapse (Figure 1C), indicating significant enrichment over time at least for certain
genes. In agreement with a very recent study,32 we also noted that mutations within known driver genes
frequently occurred simultaneously (Figure 1C), hence highlighting the need to introduce targeted nextgeneration sequencing within the diagnostic setting,13 because single-gene analysis will not suffice for
correct risk stratification and outcome prediction.
In addition to the previously mentioned genes, we detected a surprisingly high number of mutations within
RPS15 (8/41 patients, 19.5%), a gene recently found mutated at only a low frequency in CLL14,28 and
rarely described in other cancer types. Intriguingly, with the exception of a single mutation, all mutations
detected within RPS15 resided within a 7 amino-acid evolutionary conserved region; this “hotspot” of
clustered mutations points to an oncogenic rather than tumor-suppressor role of the gene. Mutations within
ribosomal genes have been identified in various syndromes or inherited conditions, mainly affecting the
erythroid lineage (eg, Diamond-Blackfan anemia); however, mutations within RPL5, RPL10, and RPL22
were recently reported in T-cell acute lymphoblastic leukemia.33,34 Prompted by our findings, we screened
a larger number of cases to not only obtain deeper insights into the frequency of RPS15 in CLL, but also,
for the first time, to investigate their association with clinicobiological features and their impact on disease
outcome. In the adverse prognostic patient group (mainly comprising U-CLL), we found that 6% of
patients carried RPS15 mutations, of which one-third (11/36) also harbored TP53 aberrations; on the other
hand, no RPS15 mutations were detected in the more favorable prognostic, IGHV-mutated CLL. Overall,
CLL patients with RPS15 mutations (without coexisting TP53 aberration) had a shorter 10-year survival
compared with wt CLL patients, and an OS similar to patients carrying other adverse-prognostic markers
(ie, 11q deletion, SF3B1/NOTCH1 mutations). Cases with concomitant RPS15 and TP53 aberrations
tended to have a worse OS than TP53 aberrant/RPS15 wt cases; however, the significance of this finding,
if any, has to be further studied. We next screened CLL patients included in the UK CLL4 trial29 and
detected 12/329 patients (3.6%) carrying RPS15 mutations. Akin to our first validation cohort,
RPS15mut/TP53wt patients had a prognosis similar to other (non-TP53) adverse-prognostic patient groups.
Finally, we analyzed 30 cases with RS and found only 1 case carrying an RPS15 mutation (also present in
the CLL phase). Hence, although RPS15 mutations appear to be linked to clinical aggressiveness in CLL,
they do not represent a mechanism underlying the histological transformation of CLL into RS.
In addition to a role in protein translation, free RPS15 has more recently been implicated in the regulation
of the MDM2-p53-MDMX-axis because it binds to MDM2 and inhibits MDM2-mediated p53
degradation.18 Using a well-characterized TP53wt cell line, we transiently expressed RPS15 mutants,
representing 2 common mutations (p.P131S and p.G132A), along with wt MDM2, and corroborated the
recently reported physical interaction between RPS15 and MDM2/MDMX.18 Although a higher binding
efficiency was seen for the RPS15P131S mutant compared with the other mutant and wt, the relevance of
this finding is currently unclear. Next, we investigated the impact of RPS15 mutants on endogenous p53
regulation and, based on 3 independent experiments, observed decreased p53 stabilization compared with
wt, in particular for the RPS15G132A mutant. In parallel, an increase of ubiquitin-mediated p53
degradation was observed in both RPS15 mutants compared with wt RPS15, pointing to reduced p53
stabilization as a consequence of higher p53 degradation. Although we cannot exclude the possibility that
RPS15 mutants may exert their activity via non-p53–mediated pathways (eg, ribosomal regulation or other
unknown functions), these data suggest a functional impairment by mutant RPS15 in regulating p53
stability compared with the wt RPS15 protein. This argument is also supported by the extreme clustering
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4768426/?report=printable
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of RPS15 mutations within an evolutionarily conserved region, alluding to altered binding properties to
MDM2 for mutant RPS15. However, our observations should be considered as preliminary, in particular
considering that the function of RPS15 has yet not been fully elucidated, and further studies are warranted
for a more in-depth analysis of the functional role of recurrent RPS15 mutations.
Recent seminal studies have revealed that subclones containing driver mutation(s) may confer adverse
outcome in CLL and that treatment may speed up the clonal selection and outgrowth of an evolutionarily
fit subclone.14,16 From these studies, genetic lesions were defined to be either clonal (ie, affecting virtually
all tumor cells) or subclonal (ie, where a proportion of the tumor cells carry a particular lesion). Although
variant allele frequencies compensated for copy-number alterations can be exploited to determine if a
somatic mutation is clonal or subclonal, groups of mutations with similarly compensated variant allele
frequencies can be assigned to clusters potentially representing clones and subclones. Following this
approach, we analyzed all mutations present at both pretreatment and relapse and assigned them to
separate clusters using the SciClone25 clustering tool. Indeed, in most cases (23/25), relapse-specific
subclones and/or clusters had expanded significantly to become the dominant clone at relapse. Contrary to
this, RPS15 mutations were detected at clonal levels before treatment in all but 1 case and remained stable
at relapse. Hence, in contrast to cases carrying subclonal lesions, which are enriched over time or after
treatment, our data imply that RPS15 mutations represent early initiating events and additional subclonal
genetic events, such as TP53 aberrations, may occur as the disease progresses.
In summary, we provide novel insights into the heterogeneous genomic landscape of relapsing CLL and
report recurrent mutations in a “hotspot” region of RPS15. Validation in a larger cohort revealed
enrichment of RPS15 mutations among cases with adverse prognosis, and in vitro characterization of 2
recurrent RPS15 mutations indicated reduced p53 stability and increased p53 degradation. Because most
RPS15 mutations were found at clonal levels even before treatment, these aberrations may represent an
early genetic event in CLL pathobiology and be linked to a more aggressive disease. Hence, we propose
recurring mutations within a ribosomal protein as a novel mechanism underlying clinical aggressiveness in
CLL, potentially linked to p53 deregulation. These findings have implications for the optimal management
of patients with CLL, raising the possibility that RPS15-mutant cases should be treated with alternative
regimens that act independently of the p53 pathway and that mutations might be worth screening at the
time of treatment decision.
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Figure 1

Somatic mutation frequencies in CLL relapsing after FCR treatment. (A) Average number of nonsynonymous
mutations in both the pretreatment and relapse samples and the number of shared mutations in the 28 samples with
matched constitutional DNA. (B) Frequency of the 6 mutation classes for pretreatment and relapse-specific mutations in
the 28 samples with matched constitutional DNA. Statistical significance was assessed using 796 pretreatment mutations
and 425 relapse-specific mutations. (C) Recurrently mutated genes. Columns represent patients (n = 41) and rows genes
or genetic lesions. Color-coding indicates the type of mutation or genomic alteration. Case names in gray were analyzed
without matched normal DNA. The majority of cases with TP53 aberrations harbored a mutation without coexisting
del(17p); this is explained by the fact that the TP53 mutation status was not known in most cases before the start of the
FCR regime in contrast to fluorescence in situ hybridization detection of del(17p), which had been performed in all cases.
All TP53 mutations were deemed damaging and have been reported previously. CNA, copy-number aberration; PR,
partial relapse; UPD, uniparental disomy.
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Figure 2

RPS15 mutations in CLL. (A) Localization of SNVs detected by either WES or with targeted resequencing of exon 4 in
the extension cohorts (data for each cohort are provided in supplemental Table 10). With the exception of a single
mutation in amino acid 33 (not shown in figure), all mutations clustered to the C-terminal of the RPS15 protein. Exons are
marked with dashed lines and the region covered in the targeted resequencing is color coded. (B) Frequency of RPS15
mutations in the FCR relapse cohort (n = 41), the extended screening cohort (n = 605), the CLL4 trial cohort (n = 329), in
RS cases (n = 30) and IGHV-mutated/stage A patients (n = 185). (C-D) Concurrent mutations and genetic lesions in
RPS15-mutated cases in the extended screening cohort and the UK CLL4 cohort. (E-F) Overall survival for subgroups
carrying recurrent cytogenetic and molecular aberrations. Pairwise log-rank test: RPS15mut vs del(13q), P < .001;
RPS15mut vs TP53abn, P = .42; RPS15mut/TP53abn vs TP53abn, P = .15; RPS15mut vs RPS15mut/TP53abn, P = .12. Tenyear survival rate for RPS15mut/TP53wt was similar to RPS15mut/TP53abn and RPS15wt/TP53abn patients (0%, 0%, and
22%, respectively), but lower than the remaining RPS15wt/TP53wt patients (59%, see supplemental Figure 7). NA, not
available.
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Figure 3

Temporal dynamics of somatic mutations. SciClone analysis of variant allele frequencies for case S42 revealed 6
predicted subclones (A). Although cluster 1 (harboring a mutation in RPS15), clusters 2 and 3 (carrying a frame-shift
deletion in MGA, a gene previously found disrupted in high-risk CLL)26,27 remained stable over time; clusters 4 and 6
represent relapse-specific (sub)clones, with the latter harboring a TP53 mutation that affects 25% of tumor cells, whereas
cluster 5 was eliminated. In case S17, a single stable population was detected; however, a drastic shift in (sub)clonal
populations was also observed (B); clusters 4 and 6 were successfully eliminated by treatment. This is noteworthy because
the former harbored the classical 2-bp deletion of NOTCH1 and the recurrent p.K700E SNV in SF3B1. On the other hand,
clusters 2, 3, and 5 represent relapse-specific subclones with cluster 2, which was the dominant clone at relapse, harboring
a stop-gain mutation in NOTCH1 and an SNV in EGR2. Results for the remaining samples are provided in supplemental
Figure 4. (A-B) The mean variant allele frequency of each cluster at both time points (top right) and the fraction of each
cluster in comparison with the major cluster (cluster 1; bottom right). (C-E) Variant allele frequencies for FCR relapsing
cases with RPS15, EGR2, and NOTCH1 mutations before treatment and at relapse. *Denote 2 unique mutations in the
same case (S17).
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Figure 4

In vitro characterization of RPS15 mutations. (A-B) RPS15G132A and RPS15P131S interact with MDM2 and MDMX.
Immunoblot analysis of whole-cell lysates (input) and immunoprecipitates (IP) of HCT116 cells cotransfected with 1 of
the Myc-DDK-RPS15 vectors (wt, G132A or P131S) and either tGFP-MDM2 (A) or tGFP-MDMX (B). Twenty-four
hours posttransfection 500 μg of cell lysates were subjected to immunoprecipitation using anti-tGFP antibody followed by
immunoblotting with indicated antibodies. Immunoglobulin G heavy chain was used as loading control for IP fraction. (CD) Transient expression of RPS15wt, RPS15P131S, and RPS15G132A in HCT116 cells revealed an impaired ability to
stabilize endogenous p53, in particular for the RPS15G132A mutant. Western blot images from 1 representative
experiment and quantification results from 3 independent experiments are shown. Images from 2 additional experiments
are presented in supplemental Figure 7. (E) Ubiquitination experiments revealed increased ubiquitin-mediated p53
degradation in both RPS15 mutants (40.1% and 40.6% increase for RPS15P131S and RPS15G132A, respectively,
measuring the intensity for the upper 4 bands) compared with wild-type RPS15.
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